Maravai LifeSciences (MRVI) Stock Price, News & Analysis

Company Overview

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.

Key Stats

• Today's Range: $8.24 to $8.99
• 50-Day Range: $7.97 to $9.73
• 52-Week Range: $4.52 to $11.56
• Volume: 3.75 million shs
• Average Volume: 2.38 million shs
• Market Capitalization: $2.13 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $10.78
• Consensus Rating: Moderate Buy

Maravai LifeSciences Stock Analysis - MarketRank™

Maravai LifeSciences scored higher than 94% of companies evaluated by MarketBeat, and ranked 170th out of 1,006 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Maravai LifeSciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 6 buy ratings, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Maravai LifeSciences has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Maravai LifeSciences are expected to grow in the coming year, from ($0.17) to ($0.15) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Maravai LifeSciences is -8.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Maravai LifeSciences is -8.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Maravai LifeSciences has a P/B Ratio of 2.69. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.33% of the outstanding shares of Maravai LifeSciences have been sold short.

Short Interest Ratio / Days to Cover

Maravai LifeSciences has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Maravai LifeSciences has recently decreased by 0.71%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Maravai LifeSciences does not currently pay a dividend.

Dividend Growth

Maravai LifeSciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.4 / 5
• Environmental Score: -1.23

Percentage of Shares Shorted

3.33% of the outstanding shares of Maravai LifeSciences have been sold short.

Short Interest Ratio / Days to Cover

Maravai LifeSciences has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Maravai LifeSciences has recently decreased by 0.71%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.88

News Sentiment

Maravai LifeSciences has a news sentiment score of 0.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for Maravai LifeSciences this week, compared to 3 articles on an average week.

Search Interest

Only 3 people have searched for MRVI on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Maravai LifeSciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -83% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Maravai LifeSciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.63% of the stock of Maravai LifeSciences is held by insiders.

Percentage Held by Institutions

50.25% of the stock of Maravai LifeSciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

MRVI Stock Analysis - Frequently Asked Questions

How have MRVI shares performed this year?

Maravai LifeSciences' stock was trading at $6.55 at the beginning of 2024. Since then, MRVI stock has increased by 28.9% and is now trading at $8.44.
View the best growth stocks for 2024 here.

How were Maravai LifeSciences' earnings last quarter?

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) released its earnings results on Wednesday, August, 7th. The company reported ($0.08) earnings per share (EPS) for the quarter. The firm's revenue was up 6.5% compared to the same quarter last year.

When did Maravai LifeSciences IPO?

Maravai LifeSciences (MRVI) raised $1.3 billion in an initial public offering on Friday, November 20th 2020. The company issued 50,000,000 shares at a price of $24.00-$27.00 per share. Morgan Stanley, Jefferies and Goldman Sachs acted as the underwriters for the IPO and BofA Securities, Credit Suisse, UBS Investment Bank, Baird, William Blair, Stifel, Keybanc Securities, Academy Securities, Loop Capital Markets, Penserra Securities and Tigress Financial Partners were co-managers.

Who are Maravai LifeSciences' major shareholders?

Maravai LifeSciences' top institutional shareholders include Gtcr LLC (8.00%), Millennium Management LLC (2.37%), Mackenzie Financial Corp (2.33%) and Massachusetts Financial Services Co. MA (1.81%).
View institutional ownership trends.

How do I buy shares of Maravai LifeSciences?

Shares of MRVI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Company Calendar

• Last Earnings: 8/07/2024
• Today: 9/20/2024
• Next Earnings (Estimated): 11/05/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: NASDAQ:MRVI
• CUSIP: N/A
• CIK: 1823239
• Web: www.maravai.com
• Phone: 858-546-0004
• Fax: N/A
• Employees: 580
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $10.78
• High Stock Price Target: $15.00
• Low Stock Price Target: $8.00
• Potential Upside/Downside: +28.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 9 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.99)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-119,030,000.00
• Net Margins: -47.41%
• Pretax Margin: 214.04%
• Return on Equity: -4.78%
• Return on Assets: -2.33%

Debt

• Debt-to-Equity Ratio: 0.71
• Current Ratio: 10.00
• Quick Ratio: 9.28

Sales & Book Value

• Annual Sales: $278.59 million
• Price / Sales: 7.58
• Cash Flow: $0.09 per share
• Price / Cash Flow: 93.03
• Book Value: $3.14 per share
• Price / Book: 2.67

Miscellaneous

• Outstanding Shares: 251,925,000
• Free Float: 250,338,000
• Market Cap: $2.11 billion
• Optionable: Optionable
• Beta: 0.01